UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation

International Journal of Cancer

Volumn 85, Issue 5, 2000, Pages 703-709

  Sugiyama, Kazuyo ^a   Shimizu, Makiko ^a   Akiyama, Tadakazu ^a   Tamaoki, Tatsuya ^a   Yamaguchi, Ken ^b   Takahashi, Rei ^c   Eastman, Alan ^d   Akinaga, Shiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; MITOMYCIN C;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ALKALOIDS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL SURVIVAL; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; DNA DAMAGE; DRUG SYNERGISM; FEMALE; G2 PHASE; GENES, P53; HUMANS; IN SITU NICK-END LABELING; MITOMYCIN; PROTEIN KINASES; S PHASE; STAUROSPORINE; TUMOR CELLS, CULTURED;

EID: 0033953099     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7     Document Type: Article

References (21)

1. AKINAGA, S., NOMURA, K., GOMI, K. and OKABE, M., Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32, 183-189 (1993).
2. 1 regulation in A431 cells synchronized at M phase by nocodazole. Anti-Cancer Drugs, 10, 67-78 (1999).
3. 1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res., 57, 1495-1501 (1997).
4. BUNCH, R.T. and EASTMAN, A., 7-hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differentiation, 8, 779-788 (1997).
5. FAN, S., SMITH, M.L., RIVET, D.J., DUBA, D., ZHAN, Q., KOHN, K.W., FORNACE JR., A.J. and O'CONNOR, P.M., Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res., 55, 1649-1654 (1995).
6. 1-acid glycoprotein. Cancer Res., 58, 3248-3253 (1998).
7. GORCZYCA, W., BRUNO, S., DARZYNKIEWICZ, R.J., GONG, J. and DARZYNKIEWICZ, Z., DNA strand breaks occurring during apoptosis: their early in situ detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int. J. Oncol., 1, 639-648 (1992).
8. HSUEH, C.-T., KELSEN, D. and SCHWARTZ, G.K., UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res., 4, 2201-2206 (1998).
9. HUSAIN, A., YAN, X.-J., ROSALES, N., AGHAJANIAN, C., SCHWARTZ, G.K. and SPRIGGS, D.R., UCN-01 in ovary cancer cells: effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status. Clin. Cancer Res., 3, 2089-2097 (1997).
10. MONKS, M., VAIGRO-WOLFF, A., HOSE, C., SAUSVILLE, E.A. and O'CONNOR, P.M., Synergistic interactions between UCN-01 and various anti-cancer agents in vitro: relationship to p53 function. Proc. Amer. Assoc. Cancer Res., 38, 322 (2157) (1997).
11. 2 delay. Cancer Res., 55, 1643-1648 (1995).
12. RUSSELL, P., Checkpoints on the road to mitosis. Trends Biochem. Sci., 23, 399-402 (1998).
13. SENDEROWICZ, A.M., HEADLEE, D., LUSH, R., ARBUCK, S., BAUER, K., FIGG, W.D., MURGO, A., INOUE, K., KOBAYASHI, S., KUWABARA, T. and SAUSVILLE, E.A., Phasetrial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Proc. Amer. Soc. clin. Oncol., 18, 612 (1999).
14. SHAO, R.-G., CAO, C.-X., SHIMIZU, T., O'CONNOR, P.M., KOHN, K.W. and POMMIER Y., Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57, 4029-4035 (1997).
15. TAMURA, T., AOYAMA. N., SAYA, H., HAGA, H., FUTAMI, S., MIYAMOTO, M., KOH, T., ARIYASU, T., TACHI, M., KASUGA, M. and TAKAHASHI, R., Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene, 11, 1939-1946 (1995).
16. TAMURA, T. and 17 OTHERS, Phasestudy of UCN-01 by 3-hour infusion. Proc. Amer. Soc. clin. Oncol., 18, 611 (1999).
17. 2 checkpoint function in cancer cells with disrupted p53. J. nat. Cancer Inst., 88, 956-965 (1996).
18. WEINSTEIN, J.N. and 20 OTHERS, An information-intensive approach to the molecular pharmacology of cancer. Science, 275, 343-349 (1997).
19. Xu, C., MEIKRANTZ, W., SCHLEGEL, R. and SAGER, R., The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. Proc. nat. Acad. Sci. (Wash.), 92, 7829-7833 (1995).
20. YU, L., GRAVES, P., WANG, P., TEMPCYZK, A., SAUSVILLE, E.A., SILVESTRINI, R., PIWNICA-WORMS, H. and O'CONNOR, P.M., The checkpoint kinase Chk1 is a target of the anticancer agent UCN-01. Proc. Amer. Assoc. Cancer Res., 40, 304 (2019)(1999).
21. 2 arrest through a cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the cdc25C phosphatase. J. biol. Chem., 273, 33455-33464 (1998).